Published in J Biol Chem on April 05, 2006
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Predicting linear B-cell epitopes using string kernels. J Mol Recognit (2008) 2.47
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature (2012) 1.93
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Isolation and characterization of a novel Betacoronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from domestic rabbits. J Virol (2012) 1.39
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog (2008) 1.27
Construction of a large naïve human phage-displayed Fab library through one-step cloning. Methods Mol Biol (2009) 1.23
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol (2014) 1.23
Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol (2008) 1.22
Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol (2013) 1.15
Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis (2010) 1.07
Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol (2012) 1.04
Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines (2014) 1.02
Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun (2015) 1.02
Receptor recognition and cross-species infections of SARS coronavirus. Antiviral Res (2013) 1.00
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs (2014) 0.96
Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion. PLoS One (2007) 0.94
Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. J Infect (2013) 0.91
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol (2014) 0.89
Chicken heat shock protein 90 is a component of the putative cellular receptor complex of infectious bursal disease virus. J Virol (2007) 0.89
Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol (2016) 0.87
Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun (2015) 0.83
Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog (2013) 0.83
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother (2013) 0.81
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs (2010) 0.76
Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res (2016) 0.75
Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. MAbs (2015) 0.75
A study of the mechanism of the chaperone-like function of an scFv of human creatine kinase by computer simulation. PLoS One (2013) 0.75
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res (2003) 8.08
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Experimental observation of the quantum anomalous Hall effect in a magnetic topological insulator. Science (2013) 4.69
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
NETWORK EXPLORATION VIA THE ADAPTIVE LASSO AND SCAD PENALTIES. Ann Appl Stat (2009) 3.91
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Nonparametric Independence Screening in Sparse Ultra-High Dimensional Additive Models. J Am Stat Assoc (2011) 2.89
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun (2003) 2.23
Structural insight into the mechanism of double-stranded RNA processing by ribonuclease III. Cell (2006) 2.15
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Noncatalytic assembly of ribonuclease III with double-stranded RNA. Structure (2004) 2.04
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther (2003) 2.01
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry (2004) 2.01
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods (2007) 1.99
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe (2009) 1.90
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Structure of RapA, a Swi2/Snf2 protein that recycles RNA polymerase during transcription. Structure (2008) 1.86
Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78. Mol Cell (2009) 1.83
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem (2006) 1.79
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol (2007) 1.71
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol (2013) 1.67
Local quasi-likelihood with a parametric guide. Ann Stat (2009) 1.65
Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol (2004) 1.61
Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun (2006) 1.58
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol (2009) 1.57
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Viruses (2009) 1.54
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A (2008) 1.49
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma (2012) 1.45
A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol (2005) 1.44
A stepwise model for double-stranded RNA processing by ribonuclease III. Mol Microbiol (2007) 1.44
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther (2006) 1.43
Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study. Leuk Lymphoma (2012) 1.42
Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding. J Virol (2008) 1.40
A ROAD to Classification in High Dimensional Space. J R Stat Soc Series B Stat Methodol (2012) 1.38
Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res (2007) 1.37
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorg Med Chem (2008) 1.31
PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem (2006) 1.30
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood (2002) 1.30
Colonization dynamics of altered Schaedler flora is influenced by gender, aging, and Helicobacter hepaticus infection in the intestines of Swiss Webster mice. Appl Environ Microbiol (2006) 1.29
Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol Pharmacol (2004) 1.27
Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol (2009) 1.27
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol (2011) 1.26
Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol (2008) 1.25
Construction of a large naïve human phage-displayed Fab library through one-step cloning. Methods Mol Biol (2009) 1.23
A spring-loaded state of NusG in its functional cycle is suggested by X-ray crystallography and supported by site-directed mutants. Biochemistry (2003) 1.22
Engineered human antibody constant domains with increased stability. J Biol Chem (2009) 1.22
Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. Virology (2007) 1.21